Aeolus Pharmaceuticals, Inc. (AOLS)

Market Cap	15.21K -97.8%
Revenue (ttm)	771.00K -68.7%
Net Income	-4.09M
EPS	-0.03
Shares Out	152.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,004
Average Volume	19,591
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0001
Beta	-68.94
RSI	48.96
Earnings Date	n/a

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: AOLS

Financial Performance

In fiscal year 2016, Aeolus Pharmaceuticals's revenue was $2.08 million, a decrease of -33.27% compared to the previous year's $3.11 million. Losses were -$6.04 million, 130.0% more than in 2015.